NCT03633396

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)

Conditions

• Palmoplantar Pustulosis

Interventions

Type	Name	Description
BIOLOGICAL	Imsidolimab	Administered by subcutaneous injection once a month
DRUG	Placebo	Administered by subcutaneous injection once a month

Timeline

• Start date: 2019-05-20
• Primary completion: 2021-04-23
• Completion: 2021-04-23
• First posted: 2018-08-16
• Last updated: 2025-09-15
• Results posted: 2022-05-31

Locations

39 sites across 4 countries: United States, Canada, Germany, Poland

Regulatory

• FDA-regulated drug study